PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer's disease

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 A, 2009, Pages 1476-1488

  Morel, Milena ^a   Couturier, Julien ^a   Lafay Chebassier, Claire ^a,b   Paccalin, Marc ^a,b   Page, Guylène ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; Apoptosis; Control of translation; MTOR; PKR

Indexed keywords

BIOLOGICAL MARKER; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE R; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; ENZYMOLOGY; HUMAN; METABOLISM; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; EIF-2 KINASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN BIOSYNTHESIS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

ANIMALIA; EUKARYOTA; MAMMALIA;

EID: 70349305529     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00849.x     Document Type: Article

References (180)

1. Lage JM. 100 Years of Alzheimer's disease (1906-2006). J Alzheimers Dis. 2006 9 : 15 26.
2. Saunders AM, Schmader K, Breitner JC, et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 1993 342 : 710 711.
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's dis-ease in late onset families. Science. 1993 261 : 921 923.
4. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associ-ated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA. 1994 91 : 11183 11186.
5. Huang DY, Goedert M, Jakes R, et al. Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neurosci Lett. 1994 182 : 55 8.
6. Poirier J, Sevigny P. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J Neural Transm Suppl. 1998 53 : 199 207. (Pubitemid 28361781)
7. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007 39 : 168 177.
8. Lee JH, Cheng R, Schupf N, et al. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol. 2007 64 : 501 506.
9. Lichtenthaler SF, Wang R, Grimm H, et al. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci USA. 1999 96 : 3053 3058.
10. Vassar R, Citron M. Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron. 2000 27 : 419 422.
11. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992 256 : 184 185.
12. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature. 1963 197 : 192 193.
13. Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis. 2006 9 : 195 207.
14. Fischer O. Die presbyophrene Demenz, deren anatomische Grundlage und Klinische Abgrenzung. Z Ges Neurol u Psychiat. 1910 3 : 371 471.
15. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007 184 : 69 91.
16. Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol. 2007 44 : 999 1010.
17. Itagaki S, McGeer PL, Akiyama H, et al. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989 24 : 173 182.
18. Rozemuller JM, Eikelenboom P, Pals ST, et al. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett. 1989 101 : 288 292.
19. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis. 2006 9 : 271 276.
20. McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci. 2004 1035 : 104 116.
21. Webster S, Lue LF, Brachova L, et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging. 1997 18 : 415 421.
22. McGeer PL, Akiyama H, Itagaki S, et al. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989 107 : 341 346.
23. Davies P. A long trek down the pathways of cell death in Alzheimer's disease. J Alzheimers Dis. 2006 9 : 265 269.
24. Nixon RA, Cataldo AM. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis. 2006 9 : 277 289.
25. van Leeuwen FW, Hol EM, Fischer DF. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system. J Alzheimers Dis. 2006 9 : 319 325.
26. Smith MA. Oxidative stress and iron imbalance in Alzheimer disease: how rust became the fuss! J Alzheimers Dis. 2006 9 : 305 308.
27. Lafay-Chebassier C, Paccalin M, Page G, et al. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem. 2005 94 : 215 225.
28. Suen KC, Yu MS, So KF, et al. Upstream signaling pathways leading to the activation of double-stranded RNA-dependent serine/threonine protein kinase in beta-amyloid peptide neurotoxicity. J Biol Chem. 2003 278 : 49819 49827.
29. Peel AL, Bredesen DE. Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice. Neurobiol Dis. 2003 14 : 52 62.
30. Chang RC, Suen KC, Ma CH, et al. Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2alpha in neuronal degeneration. J Neurochem. 2002 83 : 1215 1225.
31. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009 136 : 731 745.
32. Pain VM. Initiation of protein synthesis in eukaryotic cells. Eur J Biochem. 1996 236 : 747 771.
33. Pain VM. Initiation of protein synthesis in mammalian cells. Biochem J. 1986 235 : 625 637.
34. Merrick WC. Mechanism and regulation of eukaryotic protein synthesis. Microbiol Rev. 1992 56 : 291 315.
35. Fekete CA, Mitchell S F, Cherkasova VA, et al. N- and C-terminal residues of eIF1A have opposing effects on the fidelity of start codon selection. EMBO J. 2007 26 : 1602 1614.
36. Pestova TV, Lorsch JR, Hellen CUT. The mechanism of translation initiation in eukaryotes. In : Mathews M, Sonenberg N, Hershey JWB, editors. In translational control in biology and medicine. New York : Cold Spring Harbor Laboratory Press 2007. pp. 87 128.
37. Hinnebusch AG, Dever TE, Asano K. Mechanism of translation initiation in the yeast Saccharomyces cerevisiae. In : Mathews M, Sonenberg N, Hershey JWB, editors. In translational control in biology and medicine. New York : Cold Spring Harbor Laboratory Press 2007. pp. 225 268.
38. Chatterjee S, Pal JK. Role of 5′- and 3′-untranslated regions of mRNAs in human diseases. Biol Cell. 2009 101 : 251 262.
39. Cazzola M, Skoda RC. Translational pathophysiology: a novel molecular mechanism of human disease. Blood. 2000 95 : 3280 3288.
40. Zhou W, Song W. Leaky scanning and reinitiation regulate BACE1 gene expression. Mol Cell Biol. 2006 26 : 3353 3364.
41. Niesler B, Kapeller J, Hammer C, et al. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics. 2008 9 : 501 504.
42. Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther. 2007 15 : 2070 2079.
43. Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: A molecular 'hotspot' for pathology? Nat Med. 2000 6 : 637 641.
44. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene. 1999 18 : 6112 6120.
45. Dever TE, Feng L, Wek RC, et al. Phosphorylation of initiation factor 2 alpha by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast. Cell. 1992 68 : 585 596.
46. Ron D, Harding HP. eIF2α phosphorylation in celluar stress responses and disease. In : Mathews M, Sonenberg N, Hershey JWB, editors. In translational control in biology and medicine. New York : Cold Spring Harbor Laboratory Press 2007. pp. 345 368.
47. Ladiges W, Morton J, Blakely C, et al. Tissue specific expression of PKR protein kinase in aging B6D2F1 mice. Mech Ageing Dev. 2000 114 : 123 132.
48. Peel AL, Rao RV, Cottrell BA, et al. Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Hum Mol Genet. 2001 10 : 1531 1538.
49. Bando Y, Onuki R, Katayama T, et al. Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease. Neurochem Int. 2005 46 : 11 8.
50. Chang RC, Wong AK, Ng HK, et al. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport. 2002 13 : 2429 2432.
51. Frerichs KU, Smith CB, Brenner M, et al. Suppression of protein synthesis in brain during hibernation involves inhibition of protein initiation and elongation. Proc Natl Acad Sci USA. 1998 95 : 14511 14516.
52. Alirezaei M, Nairn AC, Glowinski J, et al. Zinc inhibits protein synthesis in neurons. Potential role of phosphorylation of translation initiation factor-2alpha. J Biol Chem. 1999 274 : 32433 32438.
53. DeGracia DJ, Adamczyk S, Folbe AJ, et al. Eukaryotic initiation factor 2alpha kinase and phosphatase activity during postischemic brain reperfusion. Exp Neurol. 1999 155 : 221 227.
54. Welsh GI, Miller CM, Loughlin AJ, et al. Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett. 1998 421 : 125 130.
55. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. 2006 9 : 309 317.
56. Romano PR, Garcia-Barrio MT, Zhang X, et al. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. Mol Cell Biol. 1998 18 : 2282 2297.
57. Bennett RL, Blalock WL, Abtahi DM, et al. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood. 2006 108 : 821 829.
58. Patel RC, Sen GC. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 1998 17 : 4379 4390.
59. Clemens MJ. Translational regulation in cell stress and apoptosis. Roles of the eIF4E binding proteins. J Cell Mol Med. 2001 5 : 221 239.
60. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res. 1997 17 : 503 524.
61. Balachandran S, Barber GN. PKR in innate immunity, cancer, and viral oncolysis. Methods Mol Biol. 2007 383 : 277 301.
62. Der SD, Yang YL, Weissmann C, et al. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA. 1997 94 : 3279 3283.
63. Srivastava SP, Kumar KU, Kaufman RJ. Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase. J Biol Chem. 1998 273 : 2416 2423.
64. Cuddihy AR, Wong AH, Tam NW, et al. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene. 1999 18 : 2690 2702.
65. Gil J, Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis. 2000 5 : 107 114. (Pubitemid 30399384)
66. Goh KC, deVeer MJ, Williams BR. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. EMBO J. 2000 19 : 4292 4297.
67. Balachandran S, Kim CN, Yeh WC, et al. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J. 1998 17 : 6888 6902.
68. Ramana CV, Grammatikakis N, Chernov M, et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J. 2000 19 : 263 272.
69. Guerra S, Lopez-Fernandez LA, Garcia MA, et al. Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. J Biol Chem. 2006 281 : 18734 18745.
70. Raught B, Gingras AC. Signaling to translation initiation. In : Mathews M, Sonenberg N, Hershey JWB, editors. In translational control in biology and medicine. New York : Cold Spring Harbor Laboratory Press 2007. pp. 369 400.
71. Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA. 2001 98 : 7037 7044.
72. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000 103 : 253 262.
73. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell. 2007 12 : 487 502.
74. De Virgilio C, Loewith R. The TOR signalling network from yeast to man. Int J Biochem Cell Biol. 2006 38 : 1476 1481.
75. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009 10 : 307 318.
76. Holz MK, Ballif BA, Gygi SP, et al. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005 123 : 569 580.
77. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res. 1999 253 : 100 109.
78. Krymskaya VP. Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal. 2003 15 : 729 739.
79. Long X, Lin Y, Ortiz-Vega S, et al. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005 15 : 702 713.
80. Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003 28 : 573 576.
81. Luo H, Duguid W, Chen H, et al. The effect of rapamycin on T cell development in mice. Eur J Immunol. 1994 24 : 692 701.
82. Ruvolo VR, Kurinna SM, Karanjeet KB, et al. PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem. 2008 283 : 35474 35485.
83. Jeffrey IW, Bushell M, Tilleray VJ, et al. Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor alpha family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase. Cancer Res. 2002 62 : 2272 2280.
84. Xu Z, Williams BR. The B56alpha regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR. Mol Cell Biol. 2000 20 : 5285 5299.
85. Tang SJ, Reis G, Kang H, et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci USA. 2002 99 : 467 472.
86. Nguyen PV. Protein synthesis during LTP: linking synaptic activity to translation. Trends Neurosci. 2002 25 : 180.
87. Langstrom NS, Anderson JP, Lindroos HG, et al. Alzheimer's disease-associated reduction of polysomal mRNA translation. Brain Res Mol Brain Res. 1989 5 : 259 269.
88. Johnson G, Gotlib J, Haroutunian V, et al. Increased phosphorylation of elongation factor 2 in Alzheimer's disease. Brain Res Mol Brain Res. 1992 15 : 319 326.
89. Lafay-Chebassier C, Perault-Pochat MC, Page G, et al. The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide. J Neurosci Res. 2006 84 : 1323 1334.
90. Casas C, Sergeant N, Itier JM, et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004 165 : 1289 1300.
91. Damjanac M, Rioux Bilan A, Paccalin M, et al. Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2008 29 : 354 367.
92. Li X, Alafuzoff I, Soininen H, et al. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005 272 : 4211 4220.
93. Li X, An WL, Alafuzoff I, et al. Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport. 2004 15 : 2237 2240.
94. Pei JJ, Hugon J. mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med. 2008 12 : 2525 2532.
95. Onuki R, Bando Y, Suyama E, et al. An RNA-dependent protein kinase is involved in tunicamycin-induced apoptosis and Alzheimer's disease. EMBO J. 2004 23 : 959 968.
96. Peel AL. PKR activation in neurodegenerative disease. J Neuropathol Exp Neurol. 2004 63 : 97 105.
97. Page G, Rioux Bilan A, Ingrand S, et al. Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer's disease. Neuroscience. 2006 139 : 1343 1354.
98. Damjanac M, Rioux Bilan A, Barrier L, et al. Fluoro-Jade B staining as useful tool to identify activated microglia and astrocytes in a mouse transgenic model of Alzheimer's disease. Brain Res. 2007 1128 : 40 9.
99. Eikelenboom P, Veerhuis R, Scheper W, et al. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm. 2006 113 : 1685 1695. (Pubitemid 44657664)
100. Hoozemans JJ, Veerhuis R, Rozemuller AJ, et al. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiol Dis. 2004 15 : 492 499.
101. Paccalin M, Pain-Barc S, Pluchon C, et al. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2006 22 : 320 326.
102. Damjanac M, Page G, Ragot S, et al. PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients. J Cell Mol Med. 2009 [Epub ahead of press].
103. Feng Z, Hu W, de Stanchina E, et al. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007 67 : 3043 3053.
104. Levine AJ, Feng Z, Mak TW, et al. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 2006 20 : 267 275.
105. Feng Z, Zhang H, Levine AJ, et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA. 2005 102 : 8204 8209.
106. Ellisen LW, Ramsayer KD, Johannessen CM, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002 10 : 995 1005.
107. Jin HO, An S, Lee HC, et al. Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal. 2007 19 : 1393 1403.
108. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004 18 : 2893 2904.
109. Corradetti MN, Inoki K, Guan KL. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. 2005 280 : 9769 9772.
110. Shoshani T, Faerman A, Mett I, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol. 2002 22 : 2283 2293.
111. Sofer A, Lei K, Johannessen CM, et al. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol. 2005 25 : 5834 5845.
112. Ellisen LW. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle. 2005 4 : 1500 1502.
113. Jozwiak J, Jozwiak S, Grzela T, et al. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med. 2005 7 : 287 296.
114. Kimball SR, Do AN, Kutzler L, et al. Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis. J Biol Chem. 2008 283 : 3465 3475.
115. Wang H, Kubica N, Ellisen LW, et al. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem. 2006 281 : 39128 39134.
116. Lanni C, Racchi M, Mazzini G, et al. Conformationally altered p53: a novel Alzheimer's disease marker? Mol Psychiatry. 2008 13 : 641 647. (Pubitemid 351704936)
117. Uberti D, Lanni C, Carsana T, et al. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging. 2006 27 : 1193 1201.
118. Lanni C, Uberti D, Racchi M, et al. Unfolded p53: a potential biomarker for Alzheimer's disease. J Alzheimers Dis. 2007 12 : 93 9.
119. Uberti D, Cenini G, Olivari L, et al. Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J Neurochem. 2007 103 : 322 333.
120. Uberti D, Carsana T, Bernardi E, et al. Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. J Cell Sci. 2002 115 : 3131 3138.
121. Baltzis D, Pluquet O, Papadakis AI, et al. The eIF2α kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. J Biol Chem. 2007 282 : 31675 31687.
122. Marques JT, Rebouillat D, Ramana CV et al. Down-regulation of p53 by double-stranded RNA modulates the antiviral response. J Virol. 2005 79 : 11105 11114.
123. Opferman JT, Zambetti GP. Translational research? Ribosome integrity and a new p53 tumor suppressor checkpoint. Cell Death Differ. 2006 13 : 898 901.
124. Paccalin M, Al Khidir F, Barc S P, et al. Peripheral p70S6k levels and emotional memory in patients with Alzheimer's disease. Neurosci Lett. 2006 410 : 162 164.
125. Rosner M, Hanneder M, Siegel N, et al. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res. 2008 658 : 234 246.
126. Shumway SD, Li Y, Xiong Y. 14-3-3beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. J Biol Chem. 2003 278 : 2089 2092.
127. DeYoung MP, Horak P, Sofer A, et al. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008 22 : 239 251.
128. Kim JR, Lee SR, Chung HJ, et al. Identification of amyloid beta-peptide responsive genes by cDNA microarray technology: involvement of RTP801 in amyloid beta-peptide toxicity. Exp Mol Med. 2003 35 : 403 411.
129. Morel M, Couturier J, Pontcharraud R et al. Evidence of molecular links between PKR and mTOR signalling pathways in Aβ neurotoxicity: role of p53, Redd1 and TSC2. Neurobiol Dis. 2009 [Epub ahead of print 22 July 2009].
130. Liu DX, Greene LA. Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res. 2001 305 : 217 228.
131. Nagy Z. Cell cycle regulatory failure in neurones: causes and consequences. Neurobiol Aging. 2000 21 : 761 769.
132. Neve RL, McPhie DL. The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol Ther. 2006 111 : 99 113.
133. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci. 1998 18 : 2801 2807.
134. McShea A, Harris PL, Webster KR, et al. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol. 1997 150 : 1933 1939.
135. Nagy Z. The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. J Cell Mol Med. 2005 9 : 531 541.
136. Nagy Z, Esiri MM, Smith AD. Expression of cell division markers in the hippocampus in Alzheimer's disease and other neu-rodegenerative conditions. Acta Neuropathol. 1997 93 : 294 300.
137. Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer's disease J Cell Biol. 1996 132 : 413 425.
138. Raven JF, Baltzis D, Wang S, et al. PKR and PKR-like endoplasmic reticulum kinase induce the proteasome-dependent degradation of cyclin D1 via a mechanism requiring eukaryotic initiation factor 2alpha phosphorylation. J Biol Chem. 2008 283 : 3097 3108.
139. Zacharek SJ, Xiong Y, Shumway SD. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res. 2005 65 : 11354 11360.
140. Lanni C, Racchi M, Mazzini G, et al. Conformationally altered p53: a novel Alzheimer's disease marker? Mol Psychiatry. 2008 13 : 641 647. (Pubitemid 351704936)
141. Tang K, Hynan LS, Baskin F, et al. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci. 2006 240 : 53 8.
142. Paccalin M, Pain-Barc S, Pluchon C, et al. The relation between p70S6k expression in lymphocytes and the decline of cognitive test scores in patients with Alzheimer disease. Arch Intern Med. 2005 165 : 2428 2429.
143. Eckert A, Schindowski K, Leutner S, et al. Alzheimer's disease-like alterations in peripheral cells from presenilin-1 transgenic mice. Neurobiol Dis. 2001 8 : 331 342.
144. Schindowski K, Kratzsch T, Peters J, et al. Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease. Neuromolecular Med. 2003 4 : 161 178.
145. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007 13 : 1359 1362.
146. Lombardi VR, Garcia M, Rey L, et al. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J Neuroimmunol. 1999 97 : 163 171.
147. Shalit F, Sredni B, Brodie C, et al. T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clin Immunol Immunopathol. 1995 75 : 246 250.
148. Juntilla MM, Koretzky GA. Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol Lett. 2008 116 : 104 110.
149. Schmitz F, Heit A, Dreher S, et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol. 2008 38 : 2981 2992.
150. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006 12 : 1005 1015.
151. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron. 2002 35 : 419 432.
152. Miscia S, Ciccocioppo F, Lanuti P, et al. Abeta(1-42) stimulated T cells express P-PKC-delta and P-PKC-zeta in Alzheimer disease. Neurobiol Aging. 2009 30 : 394 406.
153. Town T, Tan J, Flavell RA, et al. T-cells in Alzheimer's disease. Neuromolecular Med. 2005 7 : 255 264.
154. Huberman M, Sredni B, Stern L, et al. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease. J Neurol Sci. 1995 130 : 161 164.
155. Shalit F, Sredni B, Stern L, et al. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci Lett. 1994 174 : 130 132. (Pubitemid 24199480)
156. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol. 1993 47 : 169 176.
157. Jiang Y, Deacon R, Anthony DC, et al. Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases. Neurobiol Dis. 2008 32 : 125 132.
158. Itagaki S, McGeer PL, Akiyama H. Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett. 1988 91 : 259 264.
159. Rogers J, Luber-Narod J, Styren SD, et al. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988 9 : 339 349.
160. Togo T, Akiyama H, Iseki E, et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol. 2002 124 : 83 92.
161. Monsonego A, Imitola J, Zota V, et al. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid betapep-tide presentation to Th1 cells. J Immunol. 2003 171 : 2216 2224.
162. Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003 112 : 415 422.
163. Seguin R, Biernacki K, Prat A, et al. Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia. Glia. 2003 42 : 36 45.
164. Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med. 2008 12 : 762 780.
165. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000 21 : 383 421.
166. Tan J, Town T, Crawford F, et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci. 2002 5 : 1288 1293.
167. Liu YJ, Guo DW, Tian L, et al. Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-alpha-dependent. Neurobiol Aging. 2008 DOI : 10.1016/j.neurobiolaging.2008.03.024.
168. Nagy Z, Combrinck M, Budge M, et al. Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neurosci Lett. 2002 317 : 81 4.
169. Stieler JT, Lederer C, Bruckner MK, et al. Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease. Neuroreport. 2001 12 : 3969 3972.
170. Ryu EJ, Harding H P, Angelastro JM, et al. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci. 2002 22 : 10690 10698.
171. Garcia MA, Gil J, Ventoso I, et al. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev. 2006 70 : 1032 1060.
172. Gern JE, French DA, Grindle KA, et al. Double-stranded RNA induces the synthesis of specific chemokines by bronchial epithelial cells. Am J Respir Cell Mol Biol. 2003 28 : 731 737.
173. Matsukura S, Kokubu F, Kurokawa M, et al. Role of RIG-I, MDA-5, and PKR on the expression of inflammatory chemokines induced by synthetic dsRNA in airway epithelial cells. Int Arch Allergy Immunol. 2007 143 : 80 3.
174. Gil J, Alcami J, Esteban M. Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB. Mol Cell Biol. 1999 19 : 4653 4663.
175. Taddeo B, Luo TR, Zhang W, et al. Activation of NF-kappaB in cells productively infected with HSV-1 depends on activated protein kinase R and plays no apparent role in blocking apoptosis. Proc Natl Acad Sci USA. 2003 100 : 12408 12413.
176. Bonnet MC, Daurat C, Ottone C, et al. The N-terminus of PKR is responsible for the activation of the NF-kappaB signaling pathway by interacting with the IKK complex. Cell Signal. 2006 18 : 1865 1875.
177. Fontalba A, Gutierrez O, Llorca J, et al. Deficiency of CARD8 is associated with increased Alzheimer's disease risk in women. Dement Geriatr Cogn Disord. 2008 26 : 247 250.
178. Paris D, Patel N, Quadros A, et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett. 2007 415 : 11 6.
179. Gil J, Esteban M. The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors. Oncogene. 2000 19 : 3665 3674.
180. Cantarella G, Uberti D, Carsana T, et al. Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity. Cell Death Differ. 2003 10 : 134 141.